We are live on ! Find out more
ACHN

Achillion Pharmaceuticals
ACHN

Delisted

ACHN was delisted on the 27th of January, 2020.

147 hedge funds and large institutions have $853M invested in Achillion Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 56 increasing their positions, 44 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

178% more call options, than puts

Call options by funds: $10M | Put options by funds: $3.6M

27% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 44

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

2.11% less ownership

Funds ownership: 82.09% → 79.99% (-2.1%)

5% less funds holding

Funds holding: 154 → 147 (-7)

34% less capital inflows, than outflows

Capital inflows: $43.8M | Capital outflows: $66.3M

35% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 20

Holders
147
Holders Change
-7
Holders Change %
-4.55%
% of All Funds
3.91%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
13
Increased
56
Reduced
44
Closed
20
Calls
$10​M
Puts
$3.6​M
Net Calls
+$6.4​M
Net Calls Change
-⁠$4.1​M

ACHN Hedge Fund Activity: Q2 2016 in Review

147 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q2 2016, worth a combined $853M — down 1.5% from $866M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of ACHN and 13 opened new positions — a net loss of 7 holders — while 44 trimmed existing stakes and 56 added.

The largest buyer was Goldman Sachs, adding an estimated $11.9M. The largest seller was Janus Henderson Investors US, cutting an estimated $9.15M.

  • 147 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q2 2016, down from 154 in Q1 2016.
  • Funds reported $853M of Achillion Pharmaceuticals stock for Q2 2016, down 1.5% quarter-over-quarter.
  • 13 funds opened new Achillion Pharmaceuticals positions in Q2 2016 and 20 closed out, a net change of -7 holders.
  • The largest Achillion Pharmaceuticals buyer in Q2 2016 was Goldman Sachs, an estimated $11.9M added.
  • The largest Achillion Pharmaceuticals seller in Q2 2016 was Janus Henderson Investors US, an estimated $9.15M sold.

Based on aggregated 13F filings for Q2 2016.